5 completed. 3 Phase 2, 2 Phase 1.
By phase and status
Follow vupanorsen: new trials by email Literature Review of vupanorsen trials Research Report on vupanorsen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Tolerability Of Single Dose Vupanorsen In Healthy Chinese Adults
Vupanorsen - Healthy | Phase 1 | Completed | Pfizer | 18 | 2021-06-17 | 2024-03-12 |
A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)
Vupanorsen, Placebo - Dyslipidemias, Hyperlipidemias | Phase 2 | Completed | Pfizer | 286 | 2020-09-28 | 2022-10-04 |
Investigation Of Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Doses Of Vupanorsen In Japanese Healthy Adult Participants With Elevated Triglycerides
Vupanorsen, Placebo - Healthy | Phase 1 | Completed | Pfizer | 12 | 2020-08-06 | 2020-12-22 |
Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease
Placebo, ISIS 703802 40 mg, ISIS 703802 80 mg - NAFLD, Diabetes Mellitus, Type 2 | Phase 2 | Completed | Akcea Therapeutics | 105 | 2017-12-21 | 2021-02-01 |
Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)
AKCEA-ANGPTL3-LRx - Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency | Phase 2 | Completed | Akcea Therapeutics | 3 | 2017-12-21 | 2021-01-07 |
Conditions studied
Metabolic Diseases (3) · Dyslipidemias (2) · Hyperlipidemias (2) · Hyperlipoproteinemias (2) · Lipid Metabolism Disorders (2) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Digestive System Diseases (1) · Endocrine System Diseases (1) · Familial hyperchylomicronemia syndrome (1) · Fatty Liver (1) · Genetic Diseases, Inborn (1) · Glucose Metabolism Disorders (1) · Hyperlipoproteinemia Type I (1) · Hypertriglyceridemia (1)
Sponsors
Pfizer (3) · Akcea Therapeutics (2)
Countries
Canada (3) · United States (2) · China (1) · Japan (1) · Poland (1)
Results publications
PMID 35369705, PMID 37002654, PMID 38949758